Skip to content

Dr. Sofie Le Roy

Active
Private limited companyfounded 2024active for 2 yearsCardijnlaan 60, 9850 Deinze, BelgiumKBO/BCE: BE 1008.310.941
Summary

Dr. Sofie Le Roy has been active since 2024 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €104,069 and a net result of €103,069. Its solvency ranks better than 47% of 20,558 sector peers (NACE 86, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).

Overview

Activity
Specialist medical practice
NACE 86220
1 site
Size
€174,914total assets 2025
Equity
€104,069
Profit
€103,069
Turnover not published (micro format)
Financial health
95 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
< 0.1%
Structure
Accounts 13 days early
Why 95raises risk1 change of registered office in 24 monthslowers riskSector: Human health activities (NACE 86)Liquidity: current ratio 2.42, cash €99,557Figures for financial year 2025 (filed 21-04-2026)Show the evidence

Checked score

Score 2025
95 / 100
Excellent
Probability in this band: under 0.55%
Financially better than 64% of its sector peers (NACE 86, micro)
Financial strength
Strong
Solvency 84
equity 59.5% of total assets
Liquidity 81
short-term debt 40.5% · cash 56.9%
Profitability 100
return on assets 58.9%
Bankruptcy probability, 12 months
< 0.1% Very low
0%0.5%1.5%4%10%≥ 25%

Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median < 0.1% (24,098 companies, NACE 86, micro)
Last 24 months 05-2025: 0.3% 06-2025: 0.3%● unchanged vs 05-2025 07-2025: 0.3%● unchanged vs 06-2025 08-2025: 0.3%● unchanged vs 07-2025 09-2025: 0.3%● unchanged vs 08-2025 10-2025: 0.4%▲ +0.1 percentage points vs 09-2025 11-2025: 0.4%● unchanged vs 10-2025 12-2025: 0.4%● unchanged vs 11-2025 01-2026: 0.4%● unchanged vs 12-2025 02-2026: 0.4%● unchanged vs 01-2026 03-2026: 0.4%● unchanged vs 02-2026 04-2026: 0.4%● unchanged vs 03-2026highest value 05-2026: < 0.1%▼ -0.4 percentage points vs 04-2026lowest value 06-2026: < 0.1%● unchanged vs 05-2026 07-2026: < 0.1%● unchanged vs 06-2026 08-2026: < 0.1%● unchanged vs 07-2026 09-2026: < 0.1%● unchanged vs 08-2026 10-2026: < 0.1%● unchanged vs 09-2026
Credit of up to €9,000 on 30-day terms, only on tighter conditions: young company (under 3 years) without a track record
Liquidity ample (current ratio 2.42, above the usual 1.5; short-term debt: 40.5% and cash: 56.9% of total assets), and 40.5% of the assets are financed with debt and provisions.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro): better than 48% on solvency, 63% on liquidity and 80% on profitability.

The bankruptcy probability was computed on 21-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Six signals.
lowers riskraises riskneutral
lowers risk · Sector: Human health activities (NACE 86)
KBO
lowers risk · Liquidity: current ratio 2.42, cash €99,557
NBB · annual accounts
raises risk · 1 change of registered office in 24 months
Belgian Official Gazette
lowers risk · Figures for financial year 2025 (filed 21-04-2026)
NBB · annual accounts
raises risk · Young company
Founded in 2024, 2 years ago. Young companies fail more often than established ones; the risk is highest 2 to 8 years after founding.
KBO · incorporation date
Age against the risk zone
highest failure risk from 2 to 8 years 2 years 0 10 years
neutral · Latest accounts filed on time
The financial year that closed on 30-09-2025 was due by 30-04-2026 and was filed on 17-04-2026, 13 days ahead of the deadline.
NBB · 1 filing
Deviation from the deadline
2025
13 days early
← before the deadline after the deadline →
Searched, nothing found (1)
neutral · No strike-offs in the KBO publications
Searched since incorporation in 2024.
KBO publications · our coverage
  1. Registered officeRegistered-office move
  2. Annual accounts filedfinancial year 2025 · micro…
  3. IncorporationAppointment: Le Roy, Sofie (director)…

Financials · financial year 2025, micro format

Equity
€104,069
Total assets
€174,914
Net result
€103,069
Working capital
€100,654

Turnover and EBIT margin not published: the micro format does not require them.

Balance-sheet composition
Assets €174,914
Fixed assets €3,415
Current assets €171,499
Equity and liabilities €174,914
Equity €104,069
Debt €70,845
Debt finances 40.5% of the balance-sheet total.
Key figures and ratios
2025 value
EBITDA
€133,961
Cash flow
€103,393
Current ratio
2.42
Debt to equity
0.68
ROE
99.0%
ROA
58.9%
Interest coverage
64.02
Debt ≤ 1 year
€70,845
Income taxes
€28,476

Peer companies

Historical observation

Of the 39,278 companies that looked in July 2024 the way this one looks now, 1.8% went bankrupt within 24 months and 95.8% are still going.

  • Micro
  • 2 to 5 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
1.8% went bankrupt
2.3% stopped otherwise
95.8% still going

A further 0.1% stopped, but we cannot tell whether within those 24 months.

For this company itself Checked computes a lower bankruptcy probability: < 0.1% over twelve months. The score reads more about this company than the group's four characteristics; both figures are right about what they measure.

How reliable is this rule?

Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,473 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.

The companies in ten equal groups, from lowest to highest expected share.
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 1.0%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 3.0% 3.1%
10 5.6% 6.2%

The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74.5% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.

An observation about 39,278 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.

Annual accounts
Filed annual accounts As filed with the NBB · 2025 · 33 lines
Balance sheet Code2025
Assets
Total assets20/58€174,914
Fixed assets21/28€3,415
Tangible fixed assets22/27€3,415
Furniture and vehicles24€3,415
Current assets29/58€171,499
Amounts receivable within one year40/41€45,558
Trade receivables40€45,558
Cash at bank and in hand54/58€99,557
Deferred charges and accrued income490/1€26,383
Equity and liabilities
Total equity and liabilities10/49€174,914
Equity10/15€104,069
Contributions10/11€1,000
Reserves13€103,069
Distributable reserves133€103,069
Amounts payable17/49€70,845
Amounts payable within one year42/48€70,845
Trade debts44€3,067
Suppliers440/4€3,067
Taxes, remuneration and social security45€28,476
Taxes450/3€28,476
Other amounts payable47/48€39,302
Income statement Code2025
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€324
Gross operating margin9900€133,961
Operating profit (loss)9901€133,637
Financial charges65/66B€2,092
Recurring financial charges65€2,092
Profit (loss) for the period before taxes9903€131,545
Income taxes67/77€28,476
Profit (loss) for the period9904€103,069
Profit (loss) for the period to be appropriated9905€103,069
Appropriation of the result
Profit (loss) to be appropriated9906€103,069
Transfer to equity691/2€103,069
To other reserves6921€103,069

The notes to these accounts (5 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Line2025
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€324
Gross operating margin9900€133,961
Operating profit (loss)9901€133,637
Financial charges65/66B€2,092
Recurring financial charges65€2,092
Profit (loss) for the period before taxes9903€131,545
Income taxes67/77€28,476
Profit (loss) for the period9904€103,069
Profit (loss) for the period to be appropriated9905€103,069
Line2025
Assets
Total assets20/58€174,914
Fixed assets21/28€3,415
Tangible fixed assets22/27€3,415
Furniture and vehicles24€3,415
Current assets29/58€171,499
Amounts receivable within one year40/41€45,558
Trade receivables40€45,558
Cash at bank and in hand54/58€99,557
Deferred charges and accrued income490/1€26,383
Equity and liabilities
Total equity and liabilities10/49€174,914
Equity10/15€104,069
Contributions10/11€1,000
Reserves13€103,069
Distributable reserves133€103,069
Amounts payable17/49€70,845
Amounts payable within one year42/48€70,845
Trade debts44€3,067
Suppliers440/4€3,067
Taxes, remuneration and social security45€28,476
Taxes450/3€28,476
Other amounts payable47/48€39,302
Line2025
Profit (loss) for the period9904€103,069
+ Depreciation and write-downs630€324
Operating cash flow (approximation)€103,393

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Filings with the National Bank (1)
Financial year Type Filed Reference
30-09-2025 micro format 17-04-2026 2026-00083192

Similar companies · same sector, comparable size

Of the 16,579 active companies whose main activity is specialist medical practice (NACE 86220), figures are known for 8,110. 6,443 are within a factor 10 of this equity. These 5 are the closest to it. See the whole sector

Public contracts: No European public contracts awarded found since October 2016. Contracts below the EU thresholds are not in TED.

Directors

Directors
1 director, no change since 2024
Le Roy, Sofie
Director · since 15-04-2024
Current
Derived from published Gazette deeds. The KBO keeps the official list of office holders; we do not read it, so the two can differ. See the directors and other office holders in the KBO →

Mandate history

1 person since 2024, 1 in office
Show
  • Board
Mandates per person, with start and end dates
Name Functions and periods
Le Roy, Sofie
  • Director, from 15-04-2024 to date
See the board, name and registered office on a given date →

Owners and capital

Owners

No owners or capital events in the accounts and acts we read.

Group and network

Connections & network

1 current director
Depth

The network starts from this company’s directors. Other companies they run appear here as nodes.

This company Company Director Shareholding +N: links not shown yet Click a node to look further, drag to arrange, zoom with the mouse wheel.

History

Dr. Sofie Le Roy was incorporated on 11 April 2024 as a private limited company.1 The registered office was moved to Hansbeke in 2026.2 Since 2024, Le Roy, Sofie has served as director of the company.3

  1. 1KBO register
  2. 2Belgian Official Gazette, 15-05-2026
  3. 3Belgian Official Gazette, 15-04-2024

Acts, filings and financial milestones

2026
15-05
Gazette deed Registered office
Registered-office move2 facts ▸
  • Board meeting, 01-04-2026
  • Registered-office move, Cardijnlaan 60, 9850 Hansbeke
17-04
NBB filing Annual accounts filed
financial year 2025 · micro format
2024
15-04
Gazette deed Incorporation
Appointment: Le Roy, Sofie (director) · Founder · Founding capital5 facts ▸
  • Incorporation, 10-04-2024
  • Founder, Le Roy,Sofie Agnes Gabriël
  • Founding capital, €1,000
  • Registered office clause, “9890 Gavere, Vluchtenboerstraat 59” (deed in Dutch)
  • Director appointment, Le Roy, Sofie (director)
Gazette deedNBB filing
2 of 2 deeds read

Register details

Identification
Legal formPrivate limited company
Founded11-04-2024
Financial year end30-09
Activities, NACEBEL 2025
86220Specialist medical practice
21100Manufacture of basic pharmaceutical products and pharmaceutical preparations
85599Other education
E-invoicing
Reachable via Peppol
Peppol ID 0208:1008310941
Also 9925:BE1008310941
Registered 03-12-2024

If you follow this company, Checked tells you the day it leaves the Peppol register.

Register as of 21 October 2026 · Peppol Directory

Scores and ratios are computed by Checked and are not a credit decision.

Environmental permits: No permit applications found in Flanders. Brussels and Wallonia do not publish the applicant.

Sites & property

Location & real-estate footprint
Registered office, Deinze · 1 establishment unit since 2024
registered office establishment The establishment unit on the map
Ground area
506 m²
Building footprint
108 m²
Parcel 44027B0959/00H000, Flanders. Linked by address, not a title deed.
1 establishment unit
Dr. Sofie Le Roy
Cardijnlaan 60, 9850 DeinzeSpecialist medical practice
since 2024unit no. 2.361.663.750
1 parcel
Flanders 1 (100%)
Cadastral parcel Region Area Buildings Height / floors
44027B0959/00H000 Flanders 506 m² 1 · 108 m² -
How the parcels are linked
Good to know
The parcel matches the address exactly.

Articles of association

What the company does

Name clauseThe name the company operates under according to its articles.
Dr. Sofie Le Roy
Registered office clauseThe region of the registered office; it decides among other things the language of official documents.
“Vlaams Gewest” (deed in Dutch)

deed of 15-04-2024

Who represents it, and how

Who signsWho may bind the company towards others, for example by signing a contract.
“§ 3. Indien een bestuurder geen arts is, zijn diens bevoegdheden beperkt tot niet-medische aangelegenheden. § 4. Iedere bestuurder…”
Board ruleHow the board is made up, meets and takes decisions.
“Natuurlijke personen of rechtspersonen,al dan niet aandeelhouder, 1” (deed in Dutch)

deed of 15-04-2024

Meetings and financial year

Annual meetingWhen the shareholders meet each year, among other things to approve the annual accounts.
Third Friday of March at 20:00

deed of 15-04-2024

Oversight and winding up

Liquidation ruleHow assets are shared after dissolution: creditors first, then shareholders.
One provision in the deed

deed of 15-04-2024

Other provisionsOther rules from the articles that fall under none of the themes above.

Other provision: “Bevoegdheden bestuursorgaan bij één of meer bestuurders, behalve wet of statuten aan algemene vergadering voorbehouden” (deed in Dutch)
Other provision: “Toegang algemene vergadering en stemrecht, rechten niet geschorst” (deed in Dutch)
Other provision: “Bestemming winst-reserves, algemene vergadering” (deed in Dutch)
Other provision: “Uitkeringen uit winst lopende of voorgaande boekjaar, winst lopende boekjaar of winst voorgaande boekjaar zolang jaarrekening niet…” (deed in Dutch)
Liquidation distribution: “Goederen in natura opzelfde wijze verdeeld, na aanzuivering schulden, lasten, kosten of consignatie nodige sommen” (deed in Dutch)
Other provision: “Ontstaan rechtspersoonlijkheid, datum neerlegging uittreksel akte op griffie ondernemingsrechtbank” (deed in Dutch)
1 more provision in the deed, see the deed of 15-04-2024

deed of 15-04-2024